North America Acute Pancreatitis Market
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Western countries. According to the American Cancer Society, Cancer Facts & Figures 2022, the mortality rate of pancreatic cancer is predicted to be the second highest among all cancer-led mortality rates in the US by 2030. It is more likely to progress if not detected early when the tumor is resectable. According to an article published in the National Library of Medicine in 2021, only ~15% of pancreatic tumors are resectable at diagnosis, limiting five-year survival to 8%. However, the lack of early symptoms results in poor diagnosis and low resectability of these tumors. Acute pancreatitis may cause pancreatic cancer as it is an early symptom of pancreatic cancer, nearly 1% of acute pancreatitis admissions result in pancreatic cancer diagnoses. It takes several months for these patients to be diagnosed with pancreatic cancer after acute pancreatitis is diagnosed, but some suffer longer diagnostic delays due to initial misdiagnosis, which may hinder their recovery. Recurrent occurrence of acute pancreatitis leads to chronic pancreatitis, which may further increase the risk of pancreatic cancer.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, acute pancreatitis leads to ~275,000 hospital admissions each year, and this number has been increasing in the US. ~35–40% of acute pancreatitis cases in the US are due to gallstones, while alcohol consumption is the cause of 30% of cases. Pancreatitis is usually mild in 80% of patients who are admitted, and most can be discharged within a few days of their hospitalization. Acute pancreatitis is associated with a mortality rate of ~2% and has a relapse rate between 0.6% and 5.6%. Alcohol-related pancreatitis has the highest rate of relapse. According to an article published in Lancet Gastroenterology Hepatology in 2022, the global pooled incidence of acute pancreatitis is 34 cases per 100,000 per year. North America has 58.2 cases per 100,000 people per year (the US has 58.2 cases per 100,000 people per year) while Europe has 24.7 and 15.0 cases per 100,000 people in Sweden and Denmark, respectively.
Acute pancreatitis, which causes the release of digestive enzymes into the pancreatic interstitial space instead of the pancreatic duct lumen, could be an early indicator of pancreatic cancer due to tumor obstruction of the pancreatic duct. Acute pancreatitis is a painful condition, so patients seek medical care sooner, which could lead to an early cancer diagnosis. Therefore, rising cases of pancreatic cancer due to acute pancreatitis boosts the growth of the North America acute pancreatitis market.
The North America acute pancreatitis market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period. the North America acute pancreatitis market in North America is expected to grow due to the increasing burden of acute pancreatitis due to increase in cases of gallstones and excessive consumption of alcohol. Also, with an increase in technological advancement in healthcare facilities, the market in North America is expected to grow during the forecast period.
The North America acute pancreatitis market is segmented offerings, causes, end user
Based on offerings, the North America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the North America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the North America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the North America acute pancreatitis market is segmented into the US, Canada, and Mexico. The US dominated the North America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Dynavax Technologies Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the North America acute pancreatitis market.
Strategic insights for the North America Acute Pancreatitis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 3,209.63 Million |
| Market Size by 2030 | US$ 5,000.71 Million |
| Global CAGR (2022 - 2030) | 5.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Offerings
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Acute Pancreatitis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America Acute Pancreatitis Market is valued at US$ 3,209.63 Million in 2022, it is projected to reach US$ 5,000.71 Million by 2030.
As per our report North America Acute Pancreatitis Market, the market size is valued at US$ 3,209.63 Million in 2022, projecting it to reach US$ 5,000.71 Million by 2030. This translates to a CAGR of approximately 5.7% during the forecast period.
The North America Acute Pancreatitis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Acute Pancreatitis Market report:
The North America Acute Pancreatitis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Acute Pancreatitis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Acute Pancreatitis Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Acute Pancreatitis Market
